Endpoints exclusive: Bob Nelsen's Resilience snags Florida CDMO working with the Defense Department on Covid-19 antibody
Resilience has only been in existence for less than six months, but Bob Nelsen’s next-gen manufacturing play has made plenty of moves shortly after debuting with an $800 million launch round. Now, the biotech looking to change drug manufacturing is picking up a Florida CDMO partnered with the Department of Defense on a Covid-19 antibody.
Resilience is acquiring CDMO Ology Bioservices in a deal that will add two manufacturing sites to the bicoastal biotech’s footprint as well as a government-backed monoclonal antibody, a source close to the matter said Monday. Financial terms of the deal were not available.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.